In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: Yes

Abstract

Get full access to this article

View all access options for this article.

References

Medical Advisory Board of the National Multiple Sclerosis Society. Disease Management Consensus Statement. New York, NY: National Multiple Sclerosis Society, 2008.

Reynolds

Stephen

Seaman

. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Curr Med Res Opin 2010; 26: 663–674.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

O’Connor

Wolinsky

Confavreux

. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011; 365: 1293–1303.

Gold

Kappos

Arnold

. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.

Fox

Miller

Phillips

. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.

Fox

Rudick

Risk stratification and patient counseling for natalizumab in multiple sclerosis. Neurology 2012; 78: 436–437.